Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCJY35)

• Drug Name: MIN-101 Drug Info
• Synonyms: Roluperidone

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9799284
  CAS Number: CAS 359625-79-9
  TTD Drug ID: DMCJY35

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[5]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[6]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[7]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[8]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[9]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[10]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[11]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[12]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[13]

Drug(s) Targeting Sigma intracellular receptor 2 (TMEM97)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CT1812	DMBRKZ7	Alzheimer disease	8A20	Phase 2	[14]
Isoindoline derivative 5	DMIUTQW	N. A.	N. A.	Patented	[15]
Isoindoline derivative 3	DM2MYL9	N. A.	N. A.	Patented	[15]
Isoindoline derivative 4	DMP1NKI	N. A.	N. A.	Patented	[15]
Isoindoline derivative 2	DMTE0S3	N. A.	N. A.	Patented	[15]
Isoindoline derivative 1	DMD19QC	N. A.	N. A.	Patented	[15]
Benzamide derivative 9	DMVFSJZ	N. A.	N. A.	Patented	[15]
Benzamide derivative 10	DM9PKU2	N. A.	N. A.	Patented	[15]
PMID30185082-Compound-57	DMNDF1Z	N. A.	N. A.	Patented	[15]
PMID28051882-Compound-XIV	DM1RN89	N. A.	N. A.	Patented	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[2]
Sigma intracellular receptor 2 (TMEM97)	TT9NXW4	SGMR2_HUMAN	Antagonist	[3]

References

• [1] ClinicalTrials.gov (NCT03397134) Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia. U.S. National Institutes of Health.
• [2] Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [5] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [6] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [9] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [11] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [12] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [13] Clinical pipeline report, company report or official report of Lundbeck.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
• [16] Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.